DE69510207T2 - Dem Genom von minussträngigen RNA-Viren entsprechende CDNA und Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren - Google Patents

Dem Genom von minussträngigen RNA-Viren entsprechende CDNA und Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren

Info

Publication number
DE69510207T2
DE69510207T2 DE1995610207 DE69510207T DE69510207T2 DE 69510207 T2 DE69510207 T2 DE 69510207T2 DE 1995610207 DE1995610207 DE 1995610207 DE 69510207 T DE69510207 T DE 69510207T DE 69510207 T2 DE69510207 T2 DE 69510207T2
Authority
DE
Germany
Prior art keywords
minus
rna viruses
stranded rna
viruses
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1995610207
Other languages
English (en)
Other versions
DE69510207T3 (de
DE69510207D1 (de
Inventor
Martin A Billeter
Pius Spielhofer
Karin Kaelin
Frank Radecke
Henriette Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cilag GmbH International
Original Assignee
Schweiz Serum und Impfinstitut Bern
Schweiz Serum und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8219510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69510207(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schweiz Serum und Impfinstitut Bern, Schweiz Serum und Impfinstitut und Institut zur Erforschung der Infektionskrankheiten filed Critical Schweiz Serum und Impfinstitut Bern
Application granted granted Critical
Publication of DE69510207D1 publication Critical patent/DE69510207D1/de
Publication of DE69510207T2 publication Critical patent/DE69510207T2/de
Publication of DE69510207T3 publication Critical patent/DE69510207T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE1995610207 1995-08-09 1995-08-09 Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren Expired - Lifetime DE69510207T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19950112559 EP0780475B2 (de) 1995-08-09 1995-08-09 Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren

Publications (3)

Publication Number Publication Date
DE69510207D1 DE69510207D1 (de) 1999-07-15
DE69510207T2 true DE69510207T2 (de) 2000-03-23
DE69510207T3 DE69510207T3 (de) 2007-02-15

Family

ID=8219510

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1995610207 Expired - Lifetime DE69510207T3 (de) 1995-08-09 1995-08-09 Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
DE1996634407 Expired - Lifetime DE69634407T3 (de) 1995-08-09 1996-08-09 DEM ANTI-GENOM VON NICHT-SEGMENTIERTEN MINUSSTRÄNGEN RNA-VIREN ENTSPRECHENDE cDNA UND VERFAHREN ZUR HERSTELLUNG SOLCHER VIREN, WELCHE ZUSÄTZLICH ANTIGENISCH AKTIVE PROTEINE KODIEREN

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1996634407 Expired - Lifetime DE69634407T3 (de) 1995-08-09 1996-08-09 DEM ANTI-GENOM VON NICHT-SEGMENTIERTEN MINUSSTRÄNGEN RNA-VIREN ENTSPRECHENDE cDNA UND VERFAHREN ZUR HERSTELLUNG SOLCHER VIREN, WELCHE ZUSÄTZLICH ANTIGENISCH AKTIVE PROTEINE KODIEREN

Country Status (10)

Country Link
US (4) US7402429B1 (de)
EP (2) EP0780475B2 (de)
AT (2) ATE181112T1 (de)
AU (1) AU721202B2 (de)
CA (1) CA2228956C (de)
DE (2) DE69510207T3 (de)
DK (2) DK0780475T4 (de)
ES (1) ES2239336T5 (de)
PT (1) PT846181E (de)
WO (1) WO1997006270A1 (de)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) † 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
EP0780475B2 (de) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
WO1997016538A1 (fr) 1995-10-31 1997-05-09 Dnavec Research Inc. Vecteur de virus d'arn a brin negatif possedant une activite de replication autonome
CA2236378C (en) 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
ES2345643T3 (es) * 1996-07-15 2010-09-28 The Government Of The Usa, As Represented By The Department Of Health And Human Services Produccion de vacunas a base de virus respiratorio sincitial atenuado, a partir de secuencias nucleotidicas clonadas.
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7208161B1 (en) 1997-05-23 2007-04-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US6830748B1 (en) 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
KR100619319B1 (ko) 1998-06-03 2006-09-06 와이어쓰 홀딩스 코포레이션 리보핵산 바이러스의 신규 구제방법
PT1098961E (pt) 1998-06-12 2008-04-23 Mount Sinai School Of Med Of T Vírus atenuados produzidos por engenharia genética indutores de interferão
IL140264A0 (en) 1998-06-12 2002-02-10 Sinai School Medicine Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
EP0974660A1 (de) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle-Krankheitsvirus Infektiöser Klone, Impfstoffe und Diagnosetest
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
KR100746979B1 (ko) 1999-04-13 2007-08-07 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 클로닝된 뉴클레오티드 서열로부터의 약독화된 키메릭호흡기 신시티움 바이러스 백신의 제조
WO2000071578A2 (en) * 1999-05-20 2000-11-30 Cnrs Centre National De La Recherche Scientifique New polypeptides and their use for the rescue of fusion defective virus or retrovirus glycoproteins
BR0013195A (pt) 1999-07-09 2002-07-23 Government Of The Us Dept Of H Produção de vacinas de virus sincicial respiratório quimérico humano-bovino, atenuado
CN101392239A (zh) 1999-07-09 2009-03-25 美国政府健康及人类服务部 减毒的人-牛嵌合副流感病毒(piv)疫苗
US7820182B2 (en) 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
CA2380799A1 (en) * 1999-08-02 2001-02-08 American Home Products Corporation Rescue of mumps virus from cdna
AU2005237174B2 (en) * 1999-08-02 2008-08-28 Wyeth Rescue of mumps virus from CDNA
EP1217891B1 (de) * 1999-09-24 2009-12-16 Mayo Foundation For Medical Education And Research Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
IL153004A0 (en) 2000-06-23 2003-06-24 American Cyanamid Co Modified morbillivirus v proteins
US7361496B1 (en) * 2000-08-02 2008-04-22 Wyeth Rescue of mumps virus from cDNA
JPWO2002031138A1 (ja) * 2000-10-06 2004-02-19 株式会社ディナベック研究所 骨格筋に外来遺伝子を導入するためのパラミクソウイルスベクター
US20040161846A1 (en) * 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
HUP0500244A3 (en) 2001-01-19 2011-03-28 Vironovative Bv A virus causing respiratory tract illness in suspectible mammals
WO2003043587A2 (en) 2001-11-21 2003-05-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna
CA2743750A1 (en) 2002-02-21 2003-09-04 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from respiratory syncytial virus
CN1678345B (zh) 2002-04-26 2013-09-11 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
EP1375512B1 (de) * 2002-06-20 2009-07-22 Institut Pasteur Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2004096993A2 (en) 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
MXPA05013141A (es) 2003-06-09 2006-03-17 Wyeth Corp Metodo mejorado para la recuperacion de arn virus de cadena negativa, no segmentados, a partir de adnc.
EP2581093B1 (de) 2003-06-16 2015-03-18 MedImmune, LLC Influenza-Hämagglutinin- und Neuraminidase-Varianten
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
WO2005116258A2 (en) 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase varians
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
EP1856271A4 (de) 2005-03-08 2009-11-18 Medimmune Vaccines Inc Influenza-hämagglutinin- und neuraminidase-varianten
JP2008537482A (ja) 2005-03-10 2008-09-18 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、およびワクチン製剤におけるその使用および抗原配列発現用ベクターとしてのその使用、ならびにウイルスの増殖法
EP1917361A4 (de) 2005-06-21 2009-07-29 Medimmune Vaccines Inc Verfahren und zusammensetzungen zur expression von negativ-sense-virus-rna in hundezellen
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EP1945780B1 (de) 2005-10-14 2015-09-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Tollwutvirusvektorsysteme sowie zusammensetzungen und verfahren dazu
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
AU2007286161B2 (en) 2006-08-09 2013-05-02 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP1939214B1 (de) 2006-12-22 2013-07-10 Institut Pasteur Zellen und Methoden zur Generierung von Nichtsegmentierter Negativ-Strang-RNA-Viren
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
ES2523587T3 (es) 2007-06-18 2014-11-27 Medimmune, Llc Virus influenza B que tienen alteraciones en el polipéptido hemaglutinina
WO2010079505A2 (en) 2008-05-26 2010-07-15 Cadila Healthcare Limited Combined measles-human papilloma vaccine
JP2011527581A (ja) 2008-07-11 2011-11-04 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
EP2987856B1 (de) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimäre newcastle-krankheitsviren und verwendungen davon
BRPI1008549A2 (pt) 2009-02-12 2016-03-15 Medimmune Llc variantes de neuraminidase e hemaglutinina de influenza
EP2413962A1 (de) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Impfstoffe gegen das grippevirus und ihre verwendungen
BRPI1007584A2 (pt) 2009-05-05 2016-12-06 Cadila Healthcare Ltd vacina de sarampo-malária combinada, vetor de vírus de vacina de sarampo, hospedeiro e composição de vacina de sarampo-malária combinada
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
WO2011014645A1 (en) 2009-07-30 2011-02-03 Mount Sinai School Of Medicine Of New York University Influenza viruses and uses thereof
CN102741399A (zh) * 2009-10-20 2012-10-17 诺华有限公司 用于病毒拯救的改良反向遗传方法
EP2493912B1 (de) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation Rekombinante influenzaviren mit hohem titer und erhöhter replikation in vero-zellen
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP3248615A1 (de) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenzavirus-impfstoffe und verwendungen davon
EP2420242A1 (de) 2010-08-20 2012-02-22 Lauer, Ulrich M. Onkolytisches Masernvirus
WO2013046216A2 (en) 2011-06-08 2013-04-04 JOSHI Vishwas A simple two plasmid mammalian expression system for production of recombinant proteins and viruses
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
IN2014CN02114A (de) 2011-09-20 2015-05-29 Sinai School Medicine
US9951349B2 (en) * 2011-09-27 2018-04-24 Yale University Compositions and methods for transient expression of recombinant RNA
EP2780034A1 (de) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
EP2895191B1 (de) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
EP4154907A1 (de) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenzavirusimpfstoffe und verwendungen davon
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN111172120A (zh) 2013-03-14 2020-05-19 西奈山伊坎医学院 新城疫病毒及其用途
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
EP3441084A1 (de) 2014-02-27 2019-02-13 Viralytics Limited Onkolytisches virus und immunstimulator zur kombinationsbehandlung von krebs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US11535864B2 (en) 2015-01-05 2022-12-27 Vishwas Dattatraya JOSHI DNA molecules producing custom designed replicating and non-replicating negative stranded RNA viruses and uses there of
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
BR112017015789A2 (pt) 2015-02-26 2018-03-27 Boehringer Ingelheim Vetmedica Gmbh vacina de vírus da influenza suína bivalente
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途
CA2995382A1 (en) 2015-08-20 2017-02-23 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
US10973903B2 (en) 2015-08-20 2021-04-13 University Of Rochester NS1 truncated virus for the development of canine influenza vaccines
US10548966B2 (en) 2015-08-20 2020-02-04 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
CN109414488A (zh) 2016-06-03 2019-03-01 罗切斯特大学 马流感病毒减毒活疫苗
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3622078A1 (de) 2017-05-09 2020-03-18 Invectys Rekombinanter masernimpfstoff mit htert-expression
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP2021507707A (ja) 2017-12-21 2021-02-25 アンスティテュ・パストゥール ラッサワクチン
MX2020008927A (es) 2018-02-27 2021-01-08 Univ Rochester Vacuna contra la influenza atenuada viva multivalente para la prevencion y el control del virus de la influenza equina (eiv) en caballos.
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (de) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanisierte zelllinie
MX2021010343A (es) 2019-02-27 2022-01-18 Univ Rochester Vacuna para la influenza multivalente con virus vivo atenuado para la prevencion y el control del virus de la influenza equina (eiv) en caballos.
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US5869312A (en) 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
EP0702085B2 (de) * 1994-07-18 2010-01-13 Conzelmann, Karl-Klaus, Prof. Dr. Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strang-RNS-Virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
EP0780475B2 (de) * 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren

Also Published As

Publication number Publication date
CA2228956A1 (en) 1997-02-20
CA2228956C (en) 2006-07-04
DE69634407T2 (de) 2005-12-29
US7851214B2 (en) 2010-12-14
ES2239336T5 (es) 2014-03-19
DE69634407T3 (de) 2014-05-22
US20120003264A1 (en) 2012-01-05
EP0846181A1 (de) 1998-06-10
ATE290092T1 (de) 2005-03-15
ATE181112T1 (de) 1999-06-15
PT846181E (pt) 2005-07-29
ES2239336T3 (es) 2005-09-16
EP0846181B1 (de) 2005-03-02
EP0780475A1 (de) 1997-06-25
DK0780475T3 (da) 1999-11-15
EP0780475B2 (de) 2006-07-19
US20080124803A1 (en) 2008-05-29
US8158416B2 (en) 2012-04-17
DE69634407D1 (de) 2005-04-07
US7402429B1 (en) 2008-07-22
AU6820896A (en) 1997-03-05
AU721202B2 (en) 2000-06-29
US20070280961A1 (en) 2007-12-06
EP0846181B2 (de) 2013-12-11
EP0780475B1 (de) 1999-06-09
DE69510207T3 (de) 2007-02-15
US7993924B2 (en) 2011-08-09
DK0846181T4 (da) 2014-02-10
WO1997006270A1 (en) 1997-02-20
DK0846181T3 (da) 2005-07-04
DK0780475T4 (da) 2006-10-23
DE69510207D1 (de) 1999-07-15

Similar Documents

Publication Publication Date Title
ATE181112T1 (de) Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
Subbarao et al. Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation
Palese et al. Negative-strand RNA viruses: genetic engineering and applications.
Murphy et al. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics
Jorgensen et al. Cloning and nucleotide sequence of Newcastle disease virus hemagglutinin-neuraminidase mRNA: identification of a putative sialic acid binding site
Enami et al. Introduction of site-specific mutations into the genome of influenza virus.
Phillips et al. Nucleotide sequence of the 5′-terminus of Newcastle disease virus and assembly of the complete genomic sequence: agreement with the “rule of six”
WO1996010400A1 (en) Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
Gassen et al. Establishment of a rescue system for canine distemper virus
CN1871355B (zh) 从cDNA中回收非节段性负链RNA病毒的改进方法
YU17891A (sh) Dnk koja odgovara genomu virusa sa negativnim lancem rnk, i postupak za dobijanje infektivnih virusa sa negativnim lancem rnk
Radecke et al. Reverse genetics meets the nonsegmented negative-strand RNA viruses
KR20000048628A (ko) 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이
ATE172642T1 (de) Impfstoffe und verfahren zu ihrer herstellung
JP2009529861A (ja) 鳥インフルエンザウイルスのｈ５ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス
CN101952427A (zh) 产生流感病毒粒子的线性表达构建体
Collins et al. The 1A protein gene of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polycistronic transcript
CN103160473B (zh) 用于拯救麻疹病毒的组合物、试剂盒、用途及方法
Kato et al. Sendai virus gene start signals are not equivalent in reinitiation capacity: moderation at the fusion protein gene
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
IL140033A0 (en) Novel methods for rescue of rna viruses
AU2012317159B2 (en) Two plasmid mammalian expression system
ATE187496T1 (de) Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
CN105378090A (zh) 呼吸道合胞病毒半活疫苗
Sánchez et al. Conserved structures among the nucleocapsid proteins of the paramyxoviridae: complete nucleotide sequence of human parainfluenza virus type 3 NP mRNA

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings